Beeline Reports Positive Phase 2 Results for Afimetoran in SLE

Beeline Medicines reported positive Phase 2 results for afimetoran, an investigational oral, once-daily inhibitor of Toll-like receptors 7 and 8 (TLR7/8), in adults with active, moderate-to-severe systemic lupus erythematosus (SLE). Presented during a late-breaking oral session at ACR Convergence 2026, the results showed statistically significant improvements in the primary endpoint across all three evaluated doses, alongside favorable secondary efficacy outcomes and a generally manageable safety profile over 48 weeks.

Phase 2 Study Design and Primary Endpoint

The global, randomized, double-blind, placebo-controlled Phase 2 study (NCT04895696) enrolled 248 adults aged 18–70 years with active SLE despite background treatment. Participants were randomized equally to receive afimetoran at 2.5 mg, 10 mg or 30 mg once daily, or placebo, alongside permitted standard-of-care medications, including corticosteroids with a mandatory taper.

The primary endpoint was the proportion of participants achieving a SLE Responder Index-4 (SRI-4) response at Week 48. All three afimetoran doses met this endpoint, with response rates of 67.8%, 64.1% and 66.1%, respectively, compared with 34.4% for placebo. Placebo-adjusted differences ranged from 30.2 to 31.5 percentage points, with statistical significance across all doses (p<0.001).

The similar response rates across the three doses indicate consistent efficacy within the evaluated range, although they do not establish a clear dose-response relationship. This may become relevant when selecting doses for subsequent development, where efficacy must be considered alongside safety and tolerability.

Secondary Efficacy and Steroid-Sparing Outcomes

Secondary efficacy measures showed directionally consistent improvements. BILAG-based Composite Lupus Assessment (BICLA) response rates ranged from 38.7% to 50.8% across afimetoran groups, compared with 27.9% for placebo. Lupus Low Disease Activity State (LLDAS) was achieved by 35.6%–39.1% of afimetoran-treated participants versus 21.3% receiving placebo.

Steroid-sparing outcomes also favored afimetoran. A corticosteroid dose of no more than 7.5 mg/day was achieved or maintained by 71.9%–75.0% of participants across the afimetoran groups, compared with 50.0% in the placebo group. This finding is clinically relevant because reducing prolonged corticosteroid exposure is an important treatment objective in SLE, where cumulative exposure can contribute to organ damage.

Improvements were also observed in specific disease manifestations. Among participants with active skin disease at baseline, CLASI-50 responses, representing at least a 50% improvement in skin disease activity, ranged from 57.1% to 66.7%, compared with 21.4% for placebo. Joint-50 responses, indicating at least a 50% reduction in active joint counts, ranged from 61.0% to 77.1% versus 42.9%, respectively. Physician Global Assessment and SF-36 Physical Component Summary scores also showed greater improvements with afimetoran.

These findings suggest that afimetoran’s clinical activity may extend across different manifestations of SLE, although secondary endpoint results should be interpreted in the context of their exploratory or multiplicity-adjusted statistical status.

Safety and Biomarker Findings

Afimetoran was generally well tolerated across the three doses during the 48-week treatment period. Treatment-emergent adverse events occurred in 86.6% of afimetoran-treated participants compared with 79.0% receiving placebo. Infections, the most commonly reported adverse events, occurred in 60.2% versus 53.2%, respectively.

Severe treatment-emergent adverse events were reported in 3.2% of afimetoran-treated participants versus 9.7% with placebo. Treatment-emergent serious adverse events occurred in 5.9% versus 12.9%, while serious infections ranged from 0% to 3.2% across afimetoran dose groups compared with 4.8% for placebo. Adverse events leading to treatment discontinuation were also less frequent with afimetoran. No deaths were reported, and no new safety signals were identified.

Exploratory biomarker analyses showed rapid suppression of the type I interferon gene score, with near-maximal inhibition by Week 2 and sustained suppression through Week 48. Reductions in anti-double-stranded DNA (anti-dsDNA) autoantibodies and increases in complement C3 and C4 levels toward the normal range were also observed among participants with abnormal baseline values. These findings support biological activity but do not independently establish long-term disease control.

Mechanism of Action and Development Outlook

Afimetoran is an investigational, selective, equipotent oral inhibitor of TLR7 and TLR8. These receptors contribute to innate immune activation and inflammatory signalling implicated in lupus pathogenesis. Their inhibition is intended to suppress disease-associated immune pathways, including type I interferon signalling.

The FDA granted afimetoran Fast Track designation for SLE in May 2025. Beeline plans to initiate Phase 3 development in SLE in 2027. Separately, its Phase 2/3 DISCOVERY trial (NCT07881120) is evaluating afimetoran in approximately 390 adults with active cutaneous lupus erythematosus, with or without systemic manifestations. The study uses a two-stage design in which initial dose-selection findings will inform the confirmatory stage.

Clinical Significance

The Phase 2 results provide evidence of consistent clinical activity across three afimetoran doses, with improvements extending beyond overall disease activity to skin and joint manifestations and corticosteroid reduction. Sustained suppression of type I interferon signalling further supports the rationale for targeting TLR7/8 in SLE.

However, the absence of a clear dose-response relationship and the higher incidence of overall treatment-emergent adverse events compared with placebo warrant consideration during further development. The planned Phase 3 programme will be important in determining whether these efficacy findings are reproducible and whether afimetoran can establish a clinically meaningful benefit-risk profile in a larger SLE population. Afimetoran remains investigational and is not approved for use in any country.

Reference

Beeline Medicines Announces Presentation of Phase 2 Results of Afimetoran in Systemic Lupus Erythematosus at ACR Convergence 2026.Beeline Medicine, 11 November 2026

A Study Evaluating the Efficacy and Safety of Afimetoran Compared with Placebo in Participants with Active Systemic Lupus Erythematosus (SLE), ClinicalTrials.gov ID NCT04895696